Jiahong Zhong

Meizhou, 514031, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Phosphodiesterase 4 as a therapeutic target in Parkinson's disease recent advances.

Phosphodiesterase 4 as a therapeutic target in Parkinson's disease recent advances.

Journal: Experimental neurology

Published: October 25, 2025

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab.

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab.

Journal: Frontiers in pharmacology

Published: September 27, 2025

Pharmacovigilance study on old drugs repurposed for rare diseases across different indications: the case of fenfluramine.

Pharmacovigilance study on old drugs repurposed for rare diseases across different indications: the case of fenfluramine.

Journal: Frontiers in pharmacology

Published: August 09, 2025

Roflupram Reduces 6-OHDA-Induced Cellular Damage in SH-SY5Y Cells by Inhibiting PDE4.

Roflupram Reduces 6-OHDA-Induced Cellular Damage in SH-SY5Y Cells by Inhibiting PDE4.

Journal: Journal of integrative neuroscience

Published: August 02, 2025

Inhibition of PDE4 Alleviates Endoplasmic Reticulum Stress and Neuronal Damage via Activation of Nrf2/HO-1 in Parkinson's Disease.

Inhibition of PDE4 Alleviates Endoplasmic Reticulum Stress and Neuronal Damage via Activation of Nrf2/HO-1 in Parkinson's Disease.

Journal: Molecular neurobiology

Published: July 30, 2025

Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event reporting system (FAERS).

Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event reporting system (FAERS).

Journal: Frontiers in pharmacology

Published: June 09, 2025

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS).

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS).

Journal: Frontiers in pharmacology

Published: May 06, 2025

The role of T cells in the treatment of Parkinson's disease.

The role of T cells in the treatment of Parkinson's disease.

Journal: PeerJ

Published: March 14, 2025

Drug-associated infections and infestations in older adults with tumor necrosis factor-alpha inhibitors: a real-world retrospective and pharmacovigilance study.

Drug-associated infections and infestations in older adults with tumor necrosis factor-alpha inhibitors: a real-world retrospective and pharmacovigilance study.

Journal: Frontiers in pharmacology

Published: November 25, 2024

Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy.

Ponatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy.

Journal: Frontiers in pharmacology

Published: October 03, 2024

Phosphodiesterase 4 inhibition as a novel treatment for stroke.

Phosphodiesterase 4 inhibition as a novel treatment for stroke.

Journal: PeerJ

Published: September 17, 2024

Curcumin prevents neurodegeneration by blocking HDAC6-NLRP3 pathway-dependent neuroinflammation in Parkinson's disease.

Curcumin prevents neurodegeneration by blocking HDAC6-NLRP3 pathway-dependent neuroinflammation in Parkinson's disease.

Journal: International immunopharmacology

Published: September 16, 2024

Showing 1-12 of 26

Last Updated: 09/26/2026